Literature DB >> 12855570

Persistent gamma-globin expression in adult transgenic mice is mediated by HPFH-2, HPFH-3, and HPFH-6 breakpoint sequences.

Eleni Z Katsantoni1, An Langeveld, Albert W K Wai, Dubravka Drabek, Frank Grosveld, Nicholas P Anagnou, John Strouboulis.   

Abstract

Deletions at the 3' end of the human beta-globin locus are associated with the hereditary persistence of fetal hemoglobin (HPFH) in adults, potentially through the juxtaposition of enhancer elements in the vicinity of the fetal gamma-globin genes. We have tested how sequences at the HPFH-2, HPFH-3, and HPFH-6 breakpoints, which act as enhancers in vitro, affect the silencing of a locus control region A gamma (LCRA gamma) transgene in the adult stage of mice. We found persistent A gamma expression in the adult blood of most of the multicopy HPFH-2, HPFH-3, or HPFH-6 lines, in contrast to the control LCRA gamma lines which were silenced. Cre-mediated generation of single copy lines showed persistent gamma gene expression maintained in some of the HPFH-2 and HPFH-6 lines, but not in any of the HPFH-3 or LCRA gamma lines. In the HPFH-2 and HPFH-6 lines, persistent gamma gene expression correlated with euchromatic transgene integrations. Thus, our observations provide support for a model whereby HPFH conditions arise from the juxtaposition of enhancers as well as permissive chromatin subdomains in the vicinity of the gamma-globin genes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12855570     DOI: 10.1182/blood-2003-05-1681

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Control of globin gene expression during development and erythroid differentiation.

Authors:  George Stamatoyannopoulos
Journal:  Exp Hematol       Date:  2005-03       Impact factor: 3.084

2.  Multiplex-PCR assay for the deletions causing hereditary persistence of fetal hemoglobin.

Authors:  Urvashi Bhardwaj; Edward R B McCabe
Journal:  Mol Diagn       Date:  2005

Review 3.  Regulation of human fetal hemoglobin: new players, new complexities.

Authors:  Arthur Bank
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

Review 4.  Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities.

Authors:  Andrew Wilber; Arthur W Nienhuis; Derek A Persons
Journal:  Blood       Date:  2011-02-14       Impact factor: 22.113

5.  Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.

Authors:  Lin Ye; Jiaming Wang; Yuting Tan; Ashley I Beyer; Fei Xie; Marcus O Muench; Yuet Wai Kan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

6.  Synergistic effect of two β globin gene cluster mutations leading to the hereditary persistence of fetal hemoglobin (HPFH) phenotype.

Authors:  Priya Hariharan; Madhavi Sawant; Manju Gorivale; Ruma Manchanda; Roshan Colah; K Ghosh; Anita Nadkarni
Journal:  Mol Biol Rep       Date:  2017-09-06       Impact factor: 2.316

7.  The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells.

Authors:  Eleni Papanikolaou; Maria Georgomanoli; Evangelos Stamateris; Fottes Panetsos; Markisia Karagiorga; Panagiotis Tsaftaridis; Stelios Graphakos; Nicholas P Anagnou
Journal:  Hum Gene Ther       Date:  2011-12-05       Impact factor: 5.695

Review 8.  The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges.

Authors:  Michael A Goodman; Punam Malik
Journal:  Ther Adv Hematol       Date:  2016-06-25

9.  Persistent fetal gamma-globin expression in adult transgenic mice following deletion of two silencer elements located 3' to the human Agamma-globin gene.

Authors:  Maria Gazouli; Eleni Katsantoni; Theodoros Kosteas; Nicholas P Anagnou
Journal:  Mol Med       Date:  2009-08-10       Impact factor: 6.354

Review 10.  Gene therapy for hemoglobinopathies: progress and challenges.

Authors:  Alisa Dong; Stefano Rivella; Laura Breda
Journal:  Transl Res       Date:  2013-01-19       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.